Federal Reserve Chair Janet Yellen opened her statement in today’s press conference announcing “no change” to the federal funds rate, despite of a positive outlook on the US economy, based on reported improvements in the labor market, specifically an average of 230,000 new jobs in the last three months, along with growing household spending and positive consumer sentiment.

A positive outlook was announced despite of stalled wage growth, a growing number of part time employees seeking full time employment, weak business investment, downward outlook on GDP, soft net exports and weak global economic conditions.

Economic expansion and growth is expected to continue, pushing towards a 2% inflation target within 2-3 years, as well as a gradual “tightening” of monetary policy towards a target federal funds rate in the range of 3% by 2018, further increasing in the longer run.

However, Yellen goes on to say that despite of the positive outlook and current assessments of appropriate monetary policy, they will remain “accommodative” due to elevated uncertainty and the Fed is prepared to soften policy with the ability to lower interest rates down to zero to offset possible global economic pressure. Further rate increases are said to be determined on a “live” basis as new data is reported and April’s rate considerations are to be considered at that time.

Yellen was asked whether “negative” interest rates have been considered. Yellen responded by saying that it has not been a focus of discussion due to a positive economic outlook.

A downward forecast in global growth was reported, citing downward pressure from the weight of low oil prices in many countries, specifically mentioning our neighbors to the North and South, Canada and Mexico. Japan reported negative growth in the 4th quarter of 2015.

Oil is expected to stabilize due to market decline in drilling. Current consumer spending is said to be aided by current low oil prices, benefiting households by approximately $1,000 in savings per year, although, current spending was said not to be as strong as “could be”. In increase in oil prices was said to have low significance in monetary policy.

Consumer sentiment was observed to be in “solid territory” as households have been helped by low oil and stronger labor market. Yellen stated that almost all demographic groups have seen improved labor market conditions, despite inequalities existing since the 1980’s.

The FOMC meeting will be shedding light on whether the Fed plans to raise federal deposit rates, although, market consensus seems to expect little or no upward movement on near term rates due to world financial market volatility, including the European Central Bank’s recent move towards looser monetary policy and renewed quantitative easing.

The future price of gold is greatly debated between those who are bear or bull on the precious metal. On February 16th, Goldman Sachs analyst stated that it expects the Fed to rates to increase, bringing the 12 month gold price target down to $1,000. In the other hand, those tagged with being “doom & gloomers” have been bullish on gold, pointing out a near term rush to safe-haven investments in the event of a bursting world economic bubble.

The Bank for International Settlements stated in a March 4th publication that “The Federal Reserve’s interest rate lift-off in December did little to disturb the uneasy calm that had reigned in financial markets in late 2015.” and warned of the deterioration of global growth prospects.

Contrary reports highlighting positive economic growth and stability, including a report from the Bureau of Labor Statistics, which reported 242,000 new jobs created in February 2016.

The coming Fed announcements should settle some near term debate, but may raise new questions moving forward.

Nymox Pharmaceutical Corp. (NASDAQ:NYMX) reported this Wednesday that it is doing its best to undertake an analysis of the Phase 3 studies for its NX-1207 used in prostate enlargement (BPH). Thus there will be a new long term data through both the NX02-0017 as well as the NX02-0018 studies. Therefore, Nymox Pharmaceutical Corp. (NASDAQ:NYMX)thinks that it will be able to give these Phase 3 results in either Q2 or Q3 of the current year.

Both the NX02-0017 along with the NX02-0018 studies had begun back in 2009. The NX02-0017, incorporated as much as 499 patients which were randomized and this study was completed somewhere in 2012. On the other hand, the NX02-0018 incorporated 498 patients randomized thus being completed in 2013. With a post treatment of 12 months, there wasn’t any statistical significance in the treatment’s efficacy with regard to the BPH Symptom Score improvement vs controls.

The NX-1207’s safety profile was a very strong one though. CEO of Nymox Pharmaceutical Corp. (NASDAQ:NYMX), Dr. Paul Averback reported that even with the setback of the top line results not being able to beat the controls at the post treatment of 12 months in the studies.Nymox Pharmaceutical Corp. (NASDAQ:NYMX)still thinks that the NX-1207 has a lot of potential in the management of the BPH in the long term. On the other hand, added blinded protocol results from the pivotal studies have been captures thereby assessing the long term results of patients five years after the single injection given of the NX-1207 2.5 mg versus the placebo.

Nymox Pharmaceutical Corp. (NASDAQ:NYMX) had also let the market in on the fact that the financial results a day before the announcement had been made. Nymox Pharmaceutical Corp. (NASDAQ:NYMX)had stated that this showed a $0.13/share net loss on revenue amounting to as much as $331,909 with the year ending December 2014.On the other hand, NX-1207 is currently in a late development stage as well for localized prostate cancer at a low grade.

Back in 2014, NymoxPharmaceutical Corp. (NASDAQ:NYMX) had reported its eight month efficacy results which showed that there was a statistical amount of decrease in cancer progression for patients that had been given the NX-1207 as compared to the care standard.

T-Mobile (NYSE:TMUS) ended the year with more than 55 million subscribers while Sprint (NYSE:S) had 56 million users. On the other hand, the growth of T-Mobile (NYSE:TMUS) can take it a long way as 8.3 million customers were added back in 2014.

Even though it is in the fourth place, T-Mobile (NYSE:TMUS) with help from CEO John Legere, are taking on the big competitors in the market and are winning. Even though the CEO of Sprint (NYSE:S), Marcelo Claure, is trying his best to make a similar kind of identity, he only succeeded to show customers that the company is an inferior option as far as Verizon (NYSE:VZ), T-Mobile (NYSE: TMUS) and AT&T (NYSE:T) are concerned.

Sprint (NYSE:S) isn’t the largest and strongest in line and neither does it offer honesty with low prices. Sprint (NYSE:S) had been the target of headwinds in the market prior to being taken over by Claure. The company didn’t have a clear identity either, which didn’t go well with its inferior network and high prices as compared to T-Mobile (NYSE:TMUS).

On the other hand, Claure helped the company gain personality even though he is no Legere. In the last quarter, the company was able to gain 1 million in connections which was a 42% increase since the last year. This is a good start and much better as compared to losing subscribers, but the CEO still thinks that a lot has to be done for the company to pull through.

Claure stated in the press release during the company’s third quarter of fiscal 2014 that Sprint (NYSE:S) is pleased with the sales growth that it had for its quarter along with the improvement in customer base quality as it plans on starting its turnaround plan. He continued on to say that the company still has a long way to go in order to reach its goals which include lowering churn rates of postpaid customers to more competitive levels.

He also said that with the network performance improving, the company is focusing more on a strategy that can help unlock the potential of the company’s spectrum assets and he is confident regarding his plan.

The CEO may be on the right path but there is a long way for him to go as Verizon (NYSE:VZ), and AT&T (NYSE:T) are still better consumer choices with T-Mobile (NYSE:TMUS) a pricing play. Therefore, Claure has to do something to get his company in the spotlight. Its stock price hasn’t moved for quite some time now. However, stock prices work in sync with business performance and there isn’t any clear cut indication that the company will dramatically improve its performance anytime soon.

Recently, the company decided to acquire Pharmacyclics (NASDAQ:PCYC) in an agreement worth $21 billion which was probably because of its cancer-drug, Imbruvica, so that AbbVie (NYSE:ABBV) could figure out what its options are after the patent expiration. However, this may not just be enough to help the stock.

One reason is that Humira has been the most profitabole drug of the company giving it hefty sums in revenues for quite some time now. However, after expiration, they are predicted to drop as much as 20-30% in the time frame from 2017-2018. Thus, this would amount to as much as $1.5 – $2 billion of sales being lost to biosimilars trying to copy the drug.

However, the drug won’t be off of its patent in many parts of Europe up and until 2018, but there may be a loss in biosimilar entry in the European Union given that the drug will lose its exclusivity. Therefore, its company can witness a decrease in revenues by as much as $3-4 billion in 2019, based on today’s figures.

Another thing to take note of is that the buyout of Pharmacyclics (NASDAQ:PCYC) may not give AbbVie (NYSE:ABBV) enough net profit to cover up its acquisition cost before the patent for Imbruvica expires in 2026.

AbbVie (NYSE: ABBV) thinks that the drug has the potential to hit the $7 billion profit margin by 2020, and considering that the company helps the drug improve, this margin can be improved 50%. Therefore, the company will have as much as $3.5 billion extra in funds after marketing and manufacturing expenses are accounted for. Another thing to note here is that Johnson & Johnson’s (NYSE:JNJ) own half of the profits, so AbbVie (NYSE:ABBV) will have a profit of nearly $1.75 billion.

AbbVie Inc. (NYSE:ABBV) should also know that the peak sales of Imbruvica are questionable at the moment. Pharmacy befit-managers such as Express Scripts are trying their best to reduce prices of hepatitis C drugs the same way Gilead Sciences Inc. (NASDAQ:GILD) was forced to reduce its.

Imbruvica is one breakthrough treatment that can be able to charge premium prices. However, it may have to face a lot of competition in the short term. An off point may be that the experimental drug of AbbVie (NYSE: ABBV), known as ABT-199 may take a hit on the pricing structure of Imbruvica when approved. The model that Imbruvica uses at the moment doesn’t account for the price decreases or early and mid-stage competitor therapies. Instead, its profile can help charge premium prices.